Abstract
The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable (ClinicalTrials.gov NCT00006400).
Original language | English (US) |
---|---|
Pages (from-to) | 170-172 |
Number of pages | 3 |
Journal | Pediatric Blood and Cancer |
Volume | 59 |
Issue number | 1 |
DOIs | |
State | Published - Jul 15 2012 |
Keywords
- BABY HUG
- Drug toxicity
- Hydroxycarbamide
- Infant
- Poisoning
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology